Single domain antibodies and their use in cancer therapies

Patent metadata

Field	Value
Publication number	US-12594302-B2
Application number	US-202117925411-A
Country	US
Kind code	B2
Filing date	May 20, 2021
Priority date	May 20, 2020
Publication date	Apr 7, 2026
Grant date	Apr 7, 2026

Abstract

The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.

First claim

The invention claimed is:

1 . A humanized anti-FGFR4 synthetic single domain antibody (anti-FGFR4 sdAb), wherein said humanized anti-FGFR4 sdAb has the following formula FRW1-CDR1-FRW2-CDR2-FRW3-CDR3-FRW4, and wherein the CDRs are selected from the group consisting of:
a CDR1 of SEQ ID NO:1; a CDR2 of SEQ ID NO:2 and a CDR3 of SEQ ID NO:3, a CDR1 of SEQ ID NO:4; a CDR2 of SEQ ID NO:5 and a CDR3 of SEQ ID NO:6, a CDR1 of SEQ ID NO:7; a CDR2 of SEQ ID NO:8 and a CDR3 of SEQ ID NO:9, and a CDR1 of SEQ ID NO:10; a CDR2 of SEQ ID NO:11 and a CDR3 of SEQ ID NO:12.

2 . The humanized anti-FGFR4 sdAb according to claim 1 , wherein the FRW1, FRW2, FRW3 AND FRW4 consist of:
a FRW1 selected from SEQ ID NO:13 or SEQ ID NO: 17, a FRW2 selected from SEQ ID NO:14 or SEQ ID NO: 18, a FRW3 selected from SEQ ID NO:15 or SEQ ID NO: 19, a FRW4 selected from SEQ ID NO:16 or SEQ ID NO: 20,
or functional variants thereof, wherein the functional variants comprise no more than 0, 1, 2 or 3 conservative amino acid substitutions relative to SEQ ID NOs: 13-20.

3 . The humanized anti-FGFR4 sdAb according to claim 2 , comprising a sequence selected from the group consisting of: SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, and SEQ ID NO:44.

4 . The humanized anti-FGFR4 sdAb according to claim 1 , which is linked directly or indirectly, or covalently or non-covalently, to a compound of interest selected from the group consisting of: a nucleic acid, a polypeptide, a virus, a toxin and a chemical entity.

5 . The humanized anti-FGFR4 sdAb according to claim 4 , wherein the polypeptide or the chemical entity is a diagnostic compound selected from the group consisting of: an enzyme, a fluorophore, a NMR or MRI contrast agent, a radioisotope and a nanoparticle.

6 . The humanized anti-FGFR4 sdAb according to claim 4 , wherein the nucleic acid, the polypeptide, the virus, the toxin, or the chemical entity is a therapeutic compound selected from the group consisting of: cytotoxic agents, chemotherapeutic agents, radioisotopes, targeted anti-cancer agents, immunotherapeutic agents, and lytic peptides.

7 . The humanized anti-FGFR4 sdAb according to claim 1 , which is linked directly or indirectly, or covalently or non-covalently, to a drug nanocarrier, optionally wherein the drug nanocarrier comprises an organic nanocarrier.

8 . The humanized anti-FGFR4 sdAb according to claim 7 , wherein the organic nanocarrier is selected from the group consisting of: polymeric nanoparticles, liposomes, micelles and protein-based nanocarriers.

9 . The humanized ant-FGFR4 sdAb according to claim 7 , wherein the drug nanocarrier includes a therapeutic compound or a diagnostic compound, optionally wherein the therapeutic compound is a cytotoxic compound.

10 . The humanized anti-FGFR4 sdAb according to claim 1 , which is fused to an immunoglobulin domain, optionally, wherein the immunoglobulin domain is an Fc domain.

11 . A multispecific binding compound comprising at least a first synthetic single domain antibody (sdAb) comprising the humanized anti-FGFR4 sdAb as defined in claim 1 , and further comprising a second sdAb binding to a second antigen, optionally wherein the first sdAb is located at the N-terminus of the second sdAb or wherein the first sdAb is located at the C-terminus of the second sdAb.

12 . A chimeric antigen receptor (CAR) comprising (a) an antigen binding domain comprising at least a first sdAb comprising the humanized anti-FGFR4 sdAb as defined in claim 1 , and optionally a second sdAb binding to a second antigen; (b) a transmembrane domain; and (c) an intracellular domain.

13 . The CAR according to claim 12 , wherein the transmembrane domain is selected from the group consisting of the transmembrane domains of CD3zeta, CD28, CD8 alpha, DAP10, and DAP12.

14 . The CAR according to claim 12 , wherein the intracellular domain is selected from the group consisting of the intracellular domains of CD28, OX40, CD3zeta, 4-1BB, DAP10 and/or DAP1 intracellular domains, optionally wherein the intracellular domain comprises the CD3zeta and 4-1BB intracellular domains.

15 . The CAR according to claim 12 , comprising a CD8 alpha transmembrane domain and CD3zeta and 4-1BB intracellular domains.

16 . The CAR according to claim 12 , which further comprises a spacer and/or a hinge domain located between the C-terminus of the antigen binding domain and the N-terminus of the transmembrane domain, optionally wherein the hinge is the hinge of CD8 alpha.

17 . The CAR according to claim 12 , which further comprises a signal peptide located at the N-terminus of the CAR.

18 . An isolated nucleic acid encoding the humanized anti-FGFR4 sdAb according to claim 1 or encoding the CAR according to claim 12 .

19 . The isolated nucleic acid according to claim 18 , wherein the isolated nucleic acid encoding the humanized anti-FGFR4 sdAb or encoding the CAR is linked to a heterologous regulatory control sequence.

20 . A vector comprising the isolated nucleic acid of claim 18 .

21 . A host cell comprising the isolated nucleic acid according to claim 18 .

22 . An isolated cell or population of cells expressing the humanized anti-FGFR4 sdAb according to claim 1 , or the CAR according to claim 12 .

23 . The isolated cell or population of cells according to claim 22 , wherein said isolated cell or population of cells is or are an allogenic or autologous cell or cells selected from the group consisting of macrophages, NK cells, CD4+/CD8+ T cells, TILs/tumor derived CD8+ T cells, central memory CD8+ T cells, Treg cells, MAIT cells, and Yδ T cells.

24 . An in vitro or ex vivo method for diagnosing or monitoring an FGFR4 mediated cancer in a subject comprising the steps of:
a) contacting in vitro a sample from said subject with a diagnostic agent comprising the humanized anti-FGFR4 sdAb according to claim 5 , and b) determining the expression of FGFR4 in said sample.

Assignees

• Inst Curie
• Centre National De La Recherche Scient
• The Univ Of Zurich
• Honing Biosciences

Inventors

• Moutel Sandrine
• Perez Franck
• Bernasconi Michele
• Alijaj Nagjie Laila
• Gouveia Zélia

Classifications

• G01N33/575

  for cancer · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/4206

  Fibroblast growth factor receptors [FGFR] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title